A phase 2a single arm study to evaluate the effect of TCN -202 (human anti-cytomegalovirus monoclonal antibody) on CMV infection in CMV (cytomegalovirus) seronegative recipients of kidney allografts from CMV seropositive donors

Trial Profile

A phase 2a single arm study to evaluate the effect of TCN -202 (human anti-cytomegalovirus monoclonal antibody) on CMV infection in CMV (cytomegalovirus) seronegative recipients of kidney allografts from CMV seropositive donors

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2016

At a glance

  • Drugs TCN 202 (Primary)
  • Indications Cytomegalic inclusion disorders; Cytomegalovirus infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Theraclone Sciences
  • Most Recent Events

    • 26 Sep 2016 Last checked against Brazilian Clinical Trials Registry
    • 13 Dec 2013 Initiation date changed from 10 September 2013 to 27 August 2013, as per Brazilian Clinical Trials Registry record
    • 11 Dec 2013 As per Brazilian Clinical Trials Registry record, the expected date of last enrollment is 31 May 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top